Carbohydrate beverages attenuate bone resorption markers in elite runners
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO-ELSEVIER INC
Citação
METABOLISM-CLINICAL AND EXPERIMENTAL, v.63, n.12, p.1536-1541, 2014
Resumo
Objective. We evaluated the effects of carbohydrate (CHO) supplementation on markers of bone turnover in elite runners. Design. Twenty-four male runners were randomly assigned to two groups - a CHO and a control (CON) group - using a double-blind design. The participants were submitted to an overload training program (days 1-8), followed by a high-intensity intermittent running protocol (10 x 800 m) on day 9. They received a maltodextrin solution (CHO group) or a placebo solution as the CON equivalent, before, during, and after these protocols. Results. After 8 days of intensive training, baseline levels of osteocalcin (OC) decreased in both CHO and CON groups (before: 28.8 +/- 3.6 and 26.6 +/- 2.4 ng/ml, after: 24.8 +/- 3.0 and 21.9 +/- 1.6 ng/ml, respectively, p < 0.01). On day 9, at 80 min of the recovery period, carboxy-terminal of telopeptide type I collagen (CTX) serum concentration was suppressed in the CHO group (0.3 +/- 0.1 ng/ml) vs. 0.6 +/- 0.0 ng/ml for the CON group (p < 0.01). CHO supplementation was effective in decreasing CTX levels from baseline to recovery (0.5 +/- 0.1 ng/mL to 0.3 +/- 0.1 ng/mL, p < 0.001), while an increase from 0.4 +/- 0.0 ng/mL to 0.6 +/- 0.0 ng/mL (p < 0.001) was observed in the CON group. Conclusion. CHO beverage ingestion attenuated the exercise-induced increase in CTX concentration, suggesting that CHO supplementation is a potential strategy to prevent bone damage in athletes.
Palavras-chave
Bone turnover markers, CTX, PTH, Exercise, Carbohydrate supplementation
Referências
- Banfi G, 2010, SPORTS MED, V40, P697, DOI 10.2165/11533090-000000000-00000
- Bennell KL, 1996, AM J SPORT MED, V24, P211, DOI 10.1177/036354659602400217
- Chailurkit LO, 2008, CLIN ENDOCRINOL, V68, P858, DOI 10.1111/j.1365-2265.2007.03159.x
- Cheung AS, 2014, OSTEOPOROSIS INT, V25, P2027, DOI 10.1007/s00198-014-2727-0
- Cochran AJR, 2010, J APPL PHYSIOL, V108, P628, DOI 10.1152/japplphysiol.00659.2009
- de Sousa MV, 2012, EUR J APPL PHYSIOL, V112, P493, DOI 10.1007/s00421-011-2000-6
- de Sousa MV, 2010, EUR J APPL PHYSIOL, V109, P507, DOI 10.1007/s00421-010-1388-8
- Guillemant J, 2004, CALCIFIED TISSUE INT, V74, P407, DOI 10.1007/s00223-003-0070-0
- Herrmann M, 2007, CLIN CHEM LAB MED, V45, P1381, DOI 10.1515/CCLM.2007.282
- KRISTOFFERSSON A, 1995, INT J SPORTS MED, V16, P145, DOI 10.1055/s-2007-972982
- Kumar R, 2011, J CLIN ENDOCR METAB, V96, P1269, DOI 10.1210/jc.2010-2922
- Kyrou I, 2009, CURR OPIN PHARMACOL, V9, P787, DOI 10.1016/j.coph.2009.08.007
- Lippi G, 2008, CLIN CHEM, V54, P1093, DOI 10.1373/clinchem.2007.102657
- Maimoun L, 2011, METABOLISM, V60, P373, DOI 10.1016/j.metabol.2010.03.001
- Mastorakos George, 2005, Hormones (Athens), V4, P73
- Meeusen R, 2006, EUR J SPORT SCI, V6, P1, DOI 10.1080/17461390600617717
- Nattiv A, 2000, J Sci Med Sport, V3, P268, DOI 10.1016/S1440-2440(00)80036-5
- Nishiyama S, 1988, CALCIFIED TISSUE INT, V49, P373
- Nuche-Berenguer B, 2011, J ENDOCRINOL, V209, P203, DOI 10.1530/JOE-11-0015
- Oosthuyse Tanja, 2014, Appl Physiol Nutr Metab, V39, P64, DOI 10.1139/apnm-2013-0105
- Pepper M, 2006, CLIN SPORT MED, V25, P1, DOI 10.1016/j.csm.2005.08.010
- Pomerants T, 2008, J SPORT MED PHYS FIT, V48, P266
- Scott JPR, 2010, J CLIN ENDOCR METAB, V95, P3918, DOI 10.1210/jc.2009-2516
- Scott JPR, 2012, BONE, V51, P990, DOI 10.1016/j.bone.2012.08.128
- Scott JPR, 2011, J APPL PHYSIOL, V110, P423, DOI 10.1152/japplphysiol.00764.2010
- Sousa M, 2012, METABOLISM, V61, P1189, DOI 10.1016/j.metabol.2012.01.013